Bonnie A. Charpentier

Senior Vice President, Regulatory Affairs & Compliance at Cytokinetics, Inc.

Bonnie A. Charpentier

Bonnie A. Charpentier

Senior Vice President, Regulatory Affairs & Compliance at Cytokinetics, Inc.

Overview
RelSci Relationships

821

Number of Boards

1

Birthday

1952

Age

68

Relationships
RelSci Relationships are individuals Bonnie A. Charpentier likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director-Northern California Chapter at The Association of Bioscience Financial Officers

Relationship likelihood: Strong

Vice Chairman at California Biomedical Innovation Alliance

Relationship likelihood: Strong

Former Chief Financial Officer at Aridis Pharmaceuticals, Inc.

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Cytokinetics, Inc.

Relationship likelihood: Strong

Chief Human Resources & Administration Officer at Cytokinetics, Inc.

Relationship likelihood: Strong

Executive Vice President, Research & Development at Cytokinetics, Inc.

Relationship likelihood: Average

Member, Budget & Finance Committee at American Chemical Society

Relationship likelihood: Average

Former Chief Executive Officer & Executive Director at American Chemical Society

Relationship likelihood: Average

Senior Vice President, Business Development at Cytokinetics, Inc.

Relationship likelihood: Average

Senior Vice President, Research & Non-Clinical Development at Cytokinetics, Inc.

Relationship likelihood: Average

Paths to Bonnie A. Charpentier
Potential Connections via
Relationship Science
You
Bonnie A. Charpentier
Senior Vice President, Regulatory Affairs & Compliance at Cytokinetics, Inc.
Education
Undergraduate Degree
Career History
Senior Vice President, Regulatory Affairs & Compliance
2014 - Current

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Vice President-Regulatory Affairs & Quality
2007 - 2014

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Vice President, Regulatory & Quality
2001 - 2006

Genitope Corp. operates as a biotechnology company, which focuses on the research and development of novel immunotherapies for the treatment of cancer. The company was founded on August 15, 1996 and is headquartered in Redwood, CA.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bonnie A. Charpentier. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bonnie A. Charpentier's profile does not indicate a business or promotional relationship of any kind between RelSci and Bonnie A. Charpentier.